Apr 2 |
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
|
Mar 27 |
Dermata to Present at the Emerging Growth Conference on April 3, 2024
|
Mar 21 |
Dermata Therapeutics GAAP EPS of -$2.67 beats by $1.55
|
Mar 21 |
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
|
Feb 6 |
Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now
|
Feb 1 |
Dermata to Present at the Emerging Growth Conference on February 7, 2024
|
Jan 5 |
Dermata stock soars on patent issuance, partnership talks
|
Jan 4 |
Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
|
Dec 20 |
Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
|
Dec 8 |
Dermata Therapeutics files for resale of up to 7.2M shares
|